MammaPrint 70-gene profile quantifies the likelihood of recurrence for early breast cancer.

Publication Name: Expert Opinion Medical Diagnostics

Author(s): Phillipe L Bedard, Stella Mook, Martine J Piccart-Gebhart, Emiel T Rutgers, Laura J van ‘t Veer and Fatima Cardoso

Background: Over the past few years, a variety of multigene expression profiles have been developed to improve prognostication for early stage breast cancer and reduce overtreatment with chemotherapy. MammaPrint is the only test cleared by the US Food and Drug … Continued

The 70-gene prognosis-profile predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study

Publication Name: Breast Cancer Research and Treatment

Author(s): Mook, S, Schmidt, M.S., Viale, G

Purpose: The 70-gene prognosis-signature has shown to be a valid prognostic tool in node-negative breast cancer. Although axillary lymph node status is considered to be one of the most important prognostic factors, still 25–30% of node-positive breast cancer patients will … Continued